536 results about "Treatment targets" patented technology

A neurophysiological magnetic stimulation (NMS) method includes obtaining motor thresholds over one or both motor strips adhered to the patient's head or the equivalent anatomic region for treatment of non-brain, nervous system disorders. The method further includes applying magnetic stimulation coils to a therapeutic target region of the patient's brain, brainstem, spinal cord, or peripheral nervous system and applying NMS in increasing amplitudes as tolerated over the course of treatment.

The invention provides an individualized TMS target positioning method and system for spastic cerebral palsy children, and aims to realize TMS precise nerve regulation and control for different types of SCP children. According to the method, the structural features of the healthy child are obtained, and after image processing, accurate division of the SCP child brain region is achieved, the defects of a current brain injury child brain region spectrogram are overcome, and a basis is provided for seed point selection of different SCP symptoms; multi-modal image parameter features are further scanned, whole-brain voxel correlation analysis is performed based on seed points to construct functional connection diagrams, the crossed and overlapped functional connection diagrams are searched to serve as a liability focus network of different symptoms, a voxel set close to the scalp surface serves as a TMS target, and SCP child treatment targets of different clinical symptoms are accurately positioned. Based on a focus network mapping technology, functional connection characteristics related to different symptoms or symptom complexes are better positioned, a specific brain network is identified, and an accurate intervention target is provided for TMS treatment.

The invention discloses application of LECT2 as a diagnosis and treatment target of hepatic ischemia reperfusion injury. According to the present invention, the Print method operation patient sample is detected to discover that the expression of the LECT2 in the hepatic ischemia reperfusion injury is up-regulated; on the basis, a liver ischemia reperfusion injury model is constructed by knocking out a mouse through the LECT2 gene, and a result shows that the liver ischemia reperfusion injury of the mouse is obviously reduced by knocking out the LECT2 gene and transferring the LECT2-shRNA into the LECT2 gene, and the liver ischemia reperfusion injury of the mouse is aggravated by LECT2 recombinant protein; it is shown that inhibition of expression of LECT2 is beneficial to improvement or treatment of hepatic ischemia injury; furthermore, the invention further finds that liver injury can be relieved by inhibiting the combination of LECT2 and Tie1; the LECT2 / Tie1 signal channel can also be used as a target spot for treating the liver ischemia reperfusion injury.

The invention relates to the technical field of medicines, in particular to a construction method and application of a photothermal conversion platform for treating osteoarthritis by regulating synovial macrophage polarization. According to the present invention, the M2 membrane-structured black phosphorus selenium carbon body (M2-BPSeC) photo-thermal nano-platform is innovatively provided, the triple functions of bionic targeting delivery, precise thermal control intervention and immune microenvironment remodeling are integrated, and the excellent synergistic treatment effect is represented in the in-vitro cell model and the OA animal model. The technology breaks through the technical bottleneck that traditional treatment is insufficient in targeting and single in intervention dimension, precise functional coupling of the physical thermal effect and immunoregulation is achieved for the first time, and a brand new strategy of targeting-temperature control-immunity integration is provided for osteoarthritis treatment. The efficient and controllable preparation process and the remarkable multi-dimensional treatment effect open up a new path for cartilage regeneration and immune balance regulation and control.

A substrate treatment apparatus includes a nozzle, a moving mechanism, a storage portion, and a control portion. The learned model is generated by learning, as learning data, learning target speed information indicating a moving speed of the nozzle and the amount of treatment acquired by executing a treatment on a substrate that is a learning target while causing the nozzle to move at a speed based on the learning target speed information. The control portion causes speed information at the time of treatment to be outputted from the learned model by inputting a target amount of an amount of treatment to the learned model. The control portion controls a moving mechanism such that the nozzle moves at a speed based on the speed information at the time of treatment when the treatment is executed on a substrate that is a treatment target.

A small animal imaging and radiotherapy (RT) irradiator device uses a circular array x-ray source to scan an anatomy of an animal, delivers conventional and ultra-high dose rate of radiation to the treatment target. The multipixel x-ray source includes a ring of focal spots capable of irradiating x-ray beams from around fifty beam angles. The x-ray beams are collimated with a collimator designed in treatment planning.

The invention discloses a net ultrafiltration rate intelligent regulation and control device and method for CRRT treatment, and relates to the technical field of medical equipment control, and the device comprises a sensor module, a data processing module and a regulation and control module; the sensor module is used for acquiring CRRT treatment associated data of a preset patient; the data processing module is used for predicting a blood volume tolerance curve of a preset patient by utilizing an artificial intelligence technology according to historical CRRT treatment data and CRRT treatment associated data of the preset patient, and generating a net ultrafiltration rate time sequence scheme according to the predicted blood volume tolerance curve and a preset treatment target of the preset patient; and the regulation and control module is used for automatically regulating the rotating speed of a blood pump and the rotating speed of a displacement liquid pump which are used for performing CRRT treatment on the preset patient according to the net ultrafiltration rate time sequence scheme, and regulating the dehydration rate of the preset patient. According to the invention, a more accurate intelligent regulation and control mode can be provided for CRRT treatment.

The invention is applicable to the technical field of molecular biology, and provides a macrophage related gene KCNA3 and application thereof. The invention discloses a macrophage related gene KCNA3 for the first time, and the gene is identified as a macrophage related differential expression gene of a patient with type 2 diabetes mellitus with carotid atherosclerosis, and shows high expression in the patient with type 2 diabetes mellitus with carotid atherosclerosis. Through analysis of a public database transcriptome chip and high-throughput sequencing data and further verification of CIBERSORTX and WGCNA algorithms, close association between the KCNA3 gene and the macrophages is confirmed. Based on differentiated expression of the KCNA3 gene and correlation of the KCNA3 gene and macrophages, the gene can be used as a potential treatment target for further treating patients with the diabetes mellitus with the carotid atherosclerotic plaque, so that a new mechanism participating in disease progression of the diabetes mellitus with the carotid atherosclerotic plaque is disclosed.

The invention relates to the field of biological medicine, in particular to application of a reagent for measuring or regulating the expression level of HIF-1alpha in preparation of a kit for diagnosing or gout, the kit containing the reagent and a gout prediction device. The HIF-1alpha is applied as a gout diagnosis target and a treatment target for the first time, the polarization degree of Th17 cells in an inflammatory microenvironment of a gout patient can be specifically reflected, early dynamic monitoring of gout related inflammatory activities is achieved, polarization of Th17 cells and expression of related proinflammatory factors are inhibited in a targeted mode, and a new strategy is provided for prediction, diagnosis and treatment of gout.

The invention discloses a method for treating chicken chronic respiratory diseases by using MG-sEV-miRNA-200, and belongs to the technical field of exosomes, and the method comprises the following steps: step 1, constructing an MG infected cell model, and carrying out fluorescence quantitative analysis on gga-miR-200a-3p in cells / exosomes in different time periods of infection; step 2, carrying out overexpression on the miR-200 in the ACE II cells, and extracting an exosome (MG-sEV-miRNA-200) rich in the miR-200; step 3, constructing a cell model for exosome treatment, and carrying out RNA-seq sequencing to identify an exosome treatment target and a pathway rich in gga-miR-200a-3p; step 4, constructing a chick embryo model infected by MG, and injecting MG-sEV-miRNA-200 to intervene in respiratory diseases caused by MG; 5, evaluating the curative effect; mG-sEV is taken as a medium, miRNA can be protected from being influenced by RNA enzyme activity, the gga-miR-200a-3p-rich MG-sEV has the advantages of low immunogenicity, low cytotoxicity, relatively high stability, relatively high biocompatibility and the like, and the MG-sEV rich in gga-miR-200a-3p can be used for remarkably relieving lung inflammation injury caused by MG infection and reducing the bacterium carrying amount of MG in lung tissues; the method has a wide application prospect in the treatment of chicken chronic respiratory diseases.

The invention belongs to the field of biological medicine, and discloses a blood marker for identifying epilepsy convulsion and application thereof. The inventor finds that the LRG1 is obviously increased during epileptic convulsion, which indicates that the increase of the blood LRG1 is a blood marker during the acute attack stage of epileptic convulsion. The invention proposes and verifies that the LRG1 is the peripheral blood marker in the acute attack stage of epilepsy convulsion for the first time, and can be used as a clinical auxiliary diagnosis and treatment target.

The invention relates to the technical field of biological medicine, in particular to a lymphatic metastatic breast cancer treatment target and application thereof. The exosome piR-hsa-28212 disclosed by the invention can synergistically enhance VEGFC / VEGFR3 signal transduction, so that lymphatic vessel generation in breast cancer is promoted, and the potential of the exosome piR-hsa-28212 serving as a treatment target of lymphatic metastatic breast cancer is indicated. Besides, piR-hsa-28212 in the serum exosome of the breast cancer patient with lymphatic metastasis is obviously up-regulated, so that the piR-hsa-28212 can be used as a serum marker for predicting the lymphatic metastasis of the breast cancer, and has the advantages of noninvasive property, in-vitro stability, acquisition of samples and the like.

The invention discloses application of SHC3 as a diagnosis and prognosis marker and a treatment target of lung metastasis of breast cancer. The research shows that the expression of SHC3 in TNBC lung metastatic cells is remarkably up-regulated, and the up-regulation is closely related to the prognosis of TNBC patients; the increase of SHC3 expression is positively correlated with the migration ability of the TNBC cells, which proves that the SHC3 gene is obviously up-regulated in the TNBC cells of pneumophilic metastasis and can be used as a biomarker of lung metastasis of breast cancer; researches show that silence of SHC3 can significantly weaken the metastasis ability of TNBC and reduce the number of pulmonary metastasis nodules, overexpression of SHC3 can enhance the metastasis activity of TNBC, and SHC3 can be used as a therapeutic target of breast cancer pulmonary metastasis; the invention provides a new marker for prognosis of breast cancer and diagnosis of lung metastasis of breast cancer, and provides a new target and treatment strategy and direction for treatment of lung metastasis of breast cancer.

The invention discloses application of annular RNACirc3426 as a diagnostic marker and a therapeutic target of colorectal cancer. Experiments show that the Circ3426 is highly expressed in colorectal cancer cells and patient serum, and prove that the Circ3426 has good stability, and an ROC curve shows that the Circ3426 has good capacity of diagnosing colorectal cancer. Meanwhile, it is found that the molecule can promote migration and invasion ability of colorectal cancer cells, nude mouse subcutaneous tumor formation experiments prove that knock-down Circ3426 inhibits growth of tumors, and it is indicated that the molecule can serve as a treatment target of colorectal cancer. The invention provides a new diagnostic marker and a treatment target for colorectal cancer, and provides a new thought and direction for CRC diagnosis and treatment.

The invention belongs to the technical field of biological medicines, and particularly relates to application of NAT10 as a target spot in diagnosis and treatment of acute myelogenous leukemia with high expression of NAT10. The invention discloses that the NAT10 can be used as a diagnosis and treatment target of the acute myelogenous leukemia with high expression of the NAT10 for the first time, and the acute myelogenous leukemia with high expression of the NAT10 can be prevented and / or treated by adopting the NAT10 inhibitor; by detecting the content, the expression quantity and / or the activity of the NAT10, the purposes of diagnosis, monitoring, curative effect evaluation and / or prognosis evaluation of the acute myelogenous leukemia with high expression of the NAT10 can be achieved.

The invention provides an infrared physiotherapy cabin system and method based on animal and environment cooperative regulation and control, and relates to the field of animal physiotherapy and intelligent monitoring control. Comprising an animal state and cabin environment monitoring module, an infrared physiotherapy and cabin environment regulation and control module, an animal health assessment and curative effect assessment module, a personalized treatment and intelligent decision module and a man-machine interaction and safety supervision module. A credibility result is formed through multi-modal data synchronous alignment and data quality evaluation, health state characterization is constructed under credibility gating, a risk level is output, and infrared physiotherapy control parameters and cabin environment regulation and control parameters are generated through cooperative control under the constraint of a stage control boundary and a treatment target and are issued and executed. Continuously adjustable parameters are subjected to online fine adjustment in the physiotherapy process, and rollback and interlocking protection is executed when the risk is increased or the credibility is reduced; after the period is finished, the curative effect is evaluated, data recording and tracing archiving are completed, and collaborative closed-loop infrared physiotherapy regulation and control of the animal state and the in-cabin environment are achieved.

The invention relates to the crossing field of computer technology and edge calculation, and discloses a blood purification equipment real-time control method based on edge calculation. According to the method, multi-modal real-time physiological parameters, historical dialysis data and a current treatment target are fused through a local edge calculation unit, an individualized body fluid dynamic response prediction model is constructed, and an ultrafiltration rate instruction is optimized and generated within a millisecond level; the system comprises a multi-mode sensor array, a historical data storage module, a task planning interface, an edge computing unit and an ultrafiltration pump controller. According to the application, the hemodynamic state is accurately maintained, the risk of hypotension is remarkably reduced, and the treatment safety and individualization level are improved.

The invention relates to the technical field of biological medicines, and provides application of NR1D1 in treating sicca syndrome, related medicines and the like. The scheme of the invention discovers and proves that the NR1D1 gene participates in the sicca syndrome pathogenesis process, can significantly influence the function of submaxillary gland cells, and is an effective sicca syndrome immune inflammation regulation diagnosis and treatment target.

The invention discloses a wearable transcutaneous electric field stimulation system, device and equipment, the system comprises a wearing module, an electrode module and a control module, the wearing module is used for being worn on a target object; the control module is used for acquiring first illness state data, first body data and an expected treatment target; formulating a first stimulation scheme according to the data; determining a first control instruction corresponding to the first stimulation scheme; the electrode module is used for working according to the first control instruction, generating a corresponding alternating electric field in the body of the target object and stimulating the target object through the alternating electric field; the control module is also used for acquiring second illness state data and second body data; determining whether a desired treatment target is achieved; and if not, adjusting the first stimulation scheme to obtain a second stimulation scheme. According to the embodiment of the invention, a personalized stimulation scheme can be formulated.

The invention discloses application of a neutralizing antibody of oncostatin M in preparation of a medicine for treating bronchial pulmonary dysplasia. The application proves that the intrauterine inflammation can cause BPD-like lung lesion to the filial generation mouse, and the OSM expression level in the mouse lung tissue one day after the intrauterine inflammation filial generation is grown is obviously higher than that of a control group; the OSM level of the BPD group is higher than that of the non-BPD group in the umbilical blood sample of the premature infant; in-vitro experiments show that the OSM treatment can cause lung epithelial cell injury; by dripping a recombined OSM neutralizing antibody into the nose of a newborn mouse, down-regulation of the OSM level in the lung of the mouse is realized, filial generation lung injury induced by the intrauterine inflammation can be repaired, and the OSM can be used as a treatment target of the BPD caused by the intrauterine inflammation.

In one aspect, the present disclosure provides a method for identifying treatment targets relating to tumors. In another aspect, the present disclosure provides a method for identifying biomarkers and molecular features of normal and cancer cells.

The invention relates to the technical field of biomedicine, in particular to a method for regulating and controlling the liquid-liquid phase separation capacity and function of DUX4 and application of the method, and the liquid-liquid phase separation capacity and function of the DUX4 are regulated and controlled by mutating an internal disordered region of the DUX4. The invention finds that the mutation has a remarkable inhibition effect on expression of DUX4 activated totipotent genes and FSHD related genes; according to the method, an intracellular liquid-liquid phase separation model is constructed through intracellular overexpression of DUX4; a research basis and a model are provided for subsequent LLPS research of DUX4, and thinking and mechanism explanation are provided for research of DUX4-mediated facial shoulder brachial muscular dystrophy (FSHD) and development of treatment targets.

A lower leg massager includes a mechanism to enable movement of a treatment member when massaging target areas of a lower leg, that allows the treatment element mounted to the treatment member to be firmly pressed against the target areas, and that achieves an effective massage. The lower leg massager includes a vertical massage mechanism to move vertically for performing a massage operation on a calf and shin, i.e. treatment target areas. The vertical massage mechanism includes an outer treatment member which covers and presses the lateral side of the shin; a rear treatment member, disposed inwardly of the outer treatment member so as to lie behind the calf, for pressing the back side of the calf; and a pressing mechanism to enable a pressing massage to the target areas by varying the position of one of the outer treatment member and the rear treatment member.

In one aspect, the present disclosure provides a method for identifying treatment targets relating to tumors. In another aspect, the present disclosure provides a method for identifying biomarkers and molecular features of normal and cancer cells.

The invention relates to a biomarker of a glioblastoma invasion leading edge region and application of the biomarker, and belongs to the technical field of biological detection. In order to solve the technical problems of unknown tumor invasion mechanism, scarcity of treatment targets and inaccurate prognosis evaluation caused by lack of a GBM invasion leading edge region specific marker in the prior art, 12 GBM invasion leading edge region specific high-expression genes, namely CREG2, KIF5A, CELF4, TMEM132D, KHDRBS2, SNAP25, SYT1, ASIC2, PAK3, RBFOX1, STMN2 and CNTNAP2, are analyzed and screened through space transcriptomics. A COX multi-factor regression risk assessment system is developed and constructed based on the markers. According to the invention, a molecular basis is provided for accurate recognition of a GBM invasion range, patient layering and prognosis prediction, targeted therapy development and curative effect monitoring.

The invention discloses an ablation system and method for a cardiovascular balloon. The system comprises a multi-section temperature control balloon, a cooling rate control module, a flow control module, a pressure adjusting module, an intelligent feedback control module and a safety protection module. The method comprises the following steps: initializing a multi-section temperature control balloon, and deploying a cooling rate control module, a flow control module, a pressure regulation module, an intelligent feedback control module and a safety protection module; the initial temperature Ti, 0 of each section is obtained, the low temperature related to the treatment target is set as the target temperature Ti, target, and the refrigerant flow Fi, 0 and the initial pressure Pi, 0 of each section are initialized; in the real-time control stage of the freezing process, impedance change of cardiovascular tissue is monitored in real time to judge the freezing effect, and various control parameters in the cryoablation process are predicted and adjusted according to constantly changing real-time data; and monitoring whether abnormal temperature change or abnormal pressure change exists between the freezing balloon and the cardiovascular tissue, and if the abnormal temperature change or abnormal pressure change occurs, performing emergency treatment.

The invention relates to the field of biological medicine and data analysis, in particular to a method and a system for screening Alzheimer's disease diagnostic markers. The invention provides a method and a system for screening Alzheimer's disease diagnostic markers, which are used for searching key genes in AD pathology based on Mendel randomization (SMR) analysis of summarized data in combination with a multi-omics (risk gene methylation, expression and protein abundance information) research method, and revealing a regulation mechanism of the key genes in AD pathology. According to the method and the system provided by the invention, the diagnosis marker and the treatment target of the AD are further accurate, the understanding of a molecular mechanism in the AD disease is deepened, a new treatment target is found, an innovative strategy and a tool are provided for individualized treatment, and the life quality of a patient is finally improved.

The invention discloses an application of TFPI2 in preparation of an anti-hepatitis B virus drug. Through in-depth study, it is found for the first time that overexpressed TFPI2 can significantly inhibit the replication ability of HBV on the cellular level and the animal level, and the expression level of HBV DNA and HBV RNA and the secretion level of HBsAg and HBeAg are reduced. Besides, mechanism analysis finds that overexpression TFPI2 promotes degradation of hepatitis B virus X protein (HBx), the half-life period of the HBx protein is remarkably shortened, and finally the HBV replication ability is damaged. Based on the research results, the application of the TFPI2 in chronic viral hepatitis B is provided for the first time, and candidate treatment targets and backup protein drugs are provided for clinical treatment of chronic hepatitis B patients.

The invention provides a solid tumor treatment target prediction method and system based on multi-modal omics data. The solid tumor treatment target prediction method comprises the following steps: inputting multi-modal omics data of a solid tumor, calculating an affinity score, and constructing a gene-predictive factor matrix; performing priority ranking on all the input genes, and performing function enrichment analysis on the preferentially ranked genes by using a KEGG pathway set; constructing a pathway intersection network related to solid tumor progression, and identifying a sub-network enriched with high-score nodes in the pathway intersection network by adopting a restart random walk algorithm; and based on drug research and development database information, drug reutilization analysis and disturbance removal analysis are carried out on the identified sub-network enriched with the high-score nodes. The invention discloses a method for realizing multi-modal omics data integration, analysis and identification of solid tumor treatment targets and drug reutilization combination, and aims to determine treatment candidate drugs including treatment targets and reutilization drugs.

The invention provides a biomarker for cervical lesion caused by low folic acid mediated HPV infection and application of the biomarker, the biomarker is IGF2BP3 and miR-27a, and the IGF2BP3 and the miR-27a can be used as a therapeutic target and a research tool for cervical lesion caused by low folic acid mediated HPV infection. The small nucleic acid targeting IGF2BP3 and miR-27a is delivered through the folic acid modified exosome in cervical lesion treatment, and the delivery efficiency and the treatment effect are remarkably improved.